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Chronic obstructive pulmonary disease (COPD) will soon be the
third most common cause of death globally. Despite smoking
cessation, neutrophilic mucosal inﬂammation persistently dam-
ages the airways and fails to protect from recurrent infections.
This maladaptive and excess inﬂammation is also refractory to
glucocorticosteroids (GC). Here, we identify serum amyloid A
(SAA) as a candidate mediator of GC refractory inﬂammation in
COPD. Extrahepatic SAA was detected locally in COPD bronchoal-
veolar lavage ﬂuid, which correlated with IL-8 and neutrophil
elastase, consistent with neutrophil recruitment and activation.
Immunohistochemistry detected SAA was in close proximity to
airway epithelium, and in vitro SAA triggered release of IL-8 and
other proinﬂammatory mediators by airway epithelial cells in an
ALX/FPR2 (formyl peptide receptor 2) receptor-dependent manner.
Lipoxin A4 (LXA4) can also interact with ALX/FPR2 receptors and
lead to allosteric inhibition of SAA-initiated epithelial responses
(pA2 13 nM). During acute exacerbation, peripheral blood SAA lev-
els increased dramatically and were disproportionately increased
relative to LXA4. Human lung macrophages (CD68
+) colocalized
with SAA and GCs markedly increased SAA in vitro (THP-1, pEC50
43 nM). To determine its direct actions, SAA was administered into
murine lung, leading to induction of CXC chemokine ligand 1/2 and
a neutrophilic response that was inhibited by 15-epi-LXA4 but not
dexamethasone. Taken together, these ﬁndings identify SAA as
a therapeutic target for inhibition and implicate SAA as a mediator
of GC-resistant lung inﬂammation that can overwhelm organ
protective signaling by lipoxins at ALX/FPR2 receptors.
resolution | leukocyte activation | G protein-coupled receptor |
innate immunity
Airway mucosal inﬂammation is an essential effector arm ofinnate host defense, but the principal determinants of its
intensity and persistence remain poorly understood. In particu-
lar, molecular aberrations in diseases where inﬂammation is
intractable and resolution is impaired have not been well de-
lineated. Understanding these control mechanisms may help to
redress disease states, such as chronic obstructive pulmonary
disease (COPD), an incurable fatal lung disease where gluco-
corticoid (GC)-insensitive inﬂammation (reviewed in ref. 1)
persists, despite smoking cessation (2). COPD is already the ﬁfth
leading cause of death worldwide and, given its long disease la-
tency, its impact will continue to rise in coming decades (3). The
primary cause of COPD is chronic exposure to cigarette smoke,
which is known to permanently alter the lung transcriptome (4).
Because the underlying cause of persistent innate immune acti-
vation remains poorly understood in COPD, there is an urgent
need to identify new insights into the pathobiology of COPD that
will lead to novel therapeutic strategies.
The lead member of a new class of endogenous proresolving
mediators is lipoxin A4 (LXA4) (5), which is generated in the lung
during cell–cell interactions including in COPD (6), when in-
ﬁltrating leukocytes interact with airway epithelial cells (reviewed
in ref. 7). LXA4 interacts withALX/FPR2 (formyl peptide receptor
2) receptors to transduce anti-inﬂammatory signals that block
neutrophil activation and recruitment as part of a resolution pro-
gram for airway inﬂammation. For example, LXA4 opposes the
actions of the 5-lipoxygenase–derived eicosanoid leukotriene B4
(LTB4), which is a potent agonist for neutrophil transmigration and
activation (reviewed in ref. 5). Of interest, serum amyloid A (SAA)
can also interact with ALX/FPR2 receptors (8) and, in sharp
contrast to LXA4, stimulates neutrophil chemotaxis and functional
responses (9, 10). SAA is a hepatic acute-phase protein, the serum
levels of which strongly predict the intensity of acute exacerbations
of COPD (AECOPD) (11) that are triggered by airway infection
and associated with further increases in inﬂammation (12). Thus,
as SAA is increased in COPD,we reasoned that if it were present in
the lung it might account for persistent lung inﬂammation.
Here, we have shown that SAA is present in inﬂamed lungs,
elevated in AECOPD, and is closely related to neutrophilic ac-
tivation in COPD airways. During AECOPD, levels of circulating
SAAwere substantially greater than either of the anti-inﬂammatory
mediators LXA4 or annexin A1 (ANXA1), a steroid-inducible
anti-inﬂammatory protein. In vitro, SAA potently activated
proinﬂammatory mediator release from airway epithelial cells in
an ALX/FPR2-dependent manner. In vivo, SAA elicited a robust
neutrophilic response that was counteracted by administration of
the ALX/FPR2 anti-inﬂammatory ligand 15-epi-LXA4. Impor-
tantly, SAA’s proinﬂammatory actions appeared to underlie the
GC refractory nature of neutrophil-mediated inﬂammation in
COPD (and potentially other diseases of chronic neutrophilic
inﬂammation), as GCs, the most common anti-inﬂammatory drug
in current disease management, induced extrahepatic SAA ex-
pression and failed to suppress extrahepatic SAA production.
These data identify SAA as a candidate pathogenic mediator of
lung inﬂammation and mechanism for defective resolution, rais-
ing the possibility of SAA and ALX/FPR2 receptors as previously
unexplored therapeutic targets in COPD.
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Results
SAA in COPD Bronchoalveolar Lavage Fluid Is Associated with IL-8 and
Neutrophil Activation. The relationship between airway SAA and
neutrophilic inﬂammation in COPD was explored by measuring
SAA and neutrophil elastase (NE) activity, a marker of neutro-
phil activation, in bronchoalveolar lavage ﬂuid (BALF) archived
from subjects with stable (nonexacerbating) COPD. BALF SAA
levels positively correlated with NE (P = 0.001, r = 0.72,) (Fig.
1A and Table S1). In the same cohort, NE also associated with
IL-8, an independent and major neutrophil chemotactic factor
(P = 0.002, r = 0.47) (Fig. 1B) and a signiﬁcant association was
observed between SAA and IL-8 levels (Fig. 1C) (P = 0.03, r =
0.35). SAA levels in BALF collected during stable disease were
not signiﬁcantly different across the Global Initiative for Ob-
structive Lung Disease disease severity stages.
SAA Promotes Mucosal Epithelial Inﬂammatory Responses via ALX/
FPR2. In control lung, modest ALX/ FPR2 staining was observed
in airway epithelium (Fig. 2A, Upper). In COPD lung, ALX/
FPR2 expression displayed more prominent apical and baso-
lateral decoration of the airway mucosal lining (Fig. 2A, Lower),
implicating the epithelium as a potentially major target for SAA.
Staining for SAA in the same specimens demonstrated wide-
spread and intense SAA staining that was prominent within the
submucosa in close proximity to the basolateral epithelium.
Lung epithelial A549 (null-A549; deﬁcient for ALX/FPR2)
and hALX-A549 cells genetically engineered to express the
receptor were exposed to recombinant SAA. In the absence of
ALX/FPR2, SAA did not induce signiﬁcant amounts of mono-
cyte chemoattractant protein-1 (MCP-1) or GM-CSF (Fig. 2 B
and C). In the presence of ALX/FPR2, SAA markedly increased
both MCP-1 (Fig. 2B) and GM-CSF levels (Fig. 2C). In hALX-
A549 cells, SAA also induced a concentration dependent in-
crease in IL-8 (Fig. 2D). As little as 10−9 M SAA, led to 3.79 ±
1.97 ng IL-8/mL, and 50 ng SAA/mL (an SAA concentration
found in COPD BALF) (Fig. 1A) resulted in a marked increase
to 37.47 ± 7.92 ng IL-8/mL (Fig. 2D). The EC50 of SAA for
hALX-A549 generated IL-8 was 8.5 nM. In addition to A549 cells,
SAA induced production of the inﬂammatory mediators MCP-1,
GM-CSF, and IL-8 in the bronchial epithelial BEAS-2B cell line
and primary human COPD epithelial cells (Figs. S1 and S2).
Because ALX/FPR2 engagement by LXs blocks proin-
ﬂammatory mediator release by injured airway epithelial cells
(13), the impact of LXA4 and 15-epi LXA4 on SAA-initiated
IL-8 release was determined. LXA4-exposed cells demonstrated
a rightward shift in the SAA concentration response with de-
pressed maxima (Fig. 2D). Both LXA4 and 15-epi-LXA4 were
equipotent at 10−7 M, with similar IC50 values (25.74 nM for
LXA4 and 24.83 nM for 15-epi-LXA4) for SAA-mediated IL-8
release (Fig. 2 D and E). However, the rightward shift and de-
pressed SAA maxima caused by both LXs (Fig. 2 D and E),
precluded simple competitive antagonism at a single binding site
as a mechanism for inhibition of IL-8 release. We therefore
applied classic Schild regression analysis, which yielded a re-
gression slope less than unity (0.34) with an estimated pA2 of 13
nM; indicating negative cooperative binding secondary to allo-
steric modulation as the basis for antagonism.
SAA Is Disproportionately Expressed Relative to LXs During an
AECOPD in Humans. Because both SAA and LXA4 can serve as
endogenous ALX/FPR2 ligands, the relative time course of their
systemic formation was determined prospectively from the same
individual during AECOPD and Resolution. There was a trend
for increased plasma LXA4 concentrations during AECOPD
(2.0 ± 0.79 nM) vs. Resolution (0.80 ± 0.09 nM) (Fig. 3A), with
7 of 10 matching samples displaying increased LXA4 levels at
AECOPD. SAA concentrations rose sharply and were signiﬁ-
cantly elevated during AECOPD relative to Resolution (Fig. 3B)
[18,595 ± 7,112 nM (AECOPD) vs. 510 ± 800 nM (Resolution),
P < 0.05 for n = 10]. As a consequence, the amount of SAA
relative to LXA4 was signiﬁcantly increased during the acute
phase of an exacerbation (Figs. 3C) [8,791 ± 6,092 SAA/LXA4
(AECOPD) vs. 735 ± 1,305 SAA/LXA4 (Resolution), P < 0.05
for n = 10]. In addition, SAA/LXA4 ratios were determined
from a control cohort with normal lung function (Fig. 3D). The
SAA/LXA4 ratio for Control (432 ± 166 SAA/LXA4) was even
lower than AECOPD resolution (735 ± 1,305 SAA/LXA4), al-
though this difference did not reach statistical signiﬁcance at this
sample size (P = 0.25). No association between LXA4 and SAA
levels (Fig. 3E) (r = 0.152, P = 0.68) was observed during
AECOPD, whereas LXA4 and the proinﬂammatory 5-lip-
oxygenase-derived eicosanoid LTB4 were signiﬁcantly correlated
(Fig. 3F) (r= 0.87, P= 0.002). Because ANXA1 can also oppose
neutrophilic inﬂammation via its interaction with ALX/FPR2
receptors (14), plasma ANXA1 levels were determined in matched
samples. Levels for ANXA1 increased during an AECOPD (Fig.
S3A). As observed for LXA4, the levels of SAA relative to ANXA1
were also signiﬁcantly elevated during an AECOPD (Fig. S3B). In
addition, an inverse relationship between SAA and ANXA1 was
observed during AECOPD (Fig. S3C).
SAA Elicits Airway Neutrophilic Inﬂammation That Is Inhibitable by
15-epi-LXA4. To determine if the actions of SAA were opposed by
LXs in vivo, a murine airway challenge model was established.
Intranasal SAA (2 μg) challenge elicited an acute inﬂammatory
C
B
A
Fig. 1. Relationship between lung SAA, IL-8 and neutrophil activity. Cor-
relation between secreted (A) SAA and NE activity; (B) IL-8 and NE, and SAA
and IL-8 were determined in BALF from COPD subject (n = 41). (δP < 0.05,
Pearson correlation).
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response peaking at 24 h that was neutrophilic in nature (8.4 ±
1.2 × 105 BALF neutrophils at 24 h) (Fig. 4 A and B). A sig-
niﬁcant increase in secreted CXC chemokine ligand (CXCL) 1 in
BALF was seen during this early phase (6 h) (Fig. 4C). An in-
crease in transcript expression of the neutrophil chemokines,
CXCL1 and CXCL2 (the murine homologs of KC and MIP-2),
as assessed by TaqMan quantitative PCR (qPCR) (Fig. 4 D and
E), was also observed. Of note, secreted CXCL2 in BALF was
not increased above control levels, which may indicate rapid
consumption of this neutrophil chemokine at the site of SAA-
mediated inﬂammation. The murine ALX/FPR2 receptor path-
way was targeted in vivo by locally delivering 15-epi-LXA4 con-
currently with SAA, which reduced CXCL1 and CXCL2
expression by 61% and 54%, respectively (Fig. 4F). Recruitment
of BALF neutrophils was similarly reduced by 15-epi-LXA4 at
early (6 h) and peak (24 h) time points, respectively (Fig. 4G and
H). In contrast to 15-epi-LXA4, when dexamethasone (DEX)
(0.5 mg/kg, i.p.) was given 2 h before SAA challenge, there was
no signiﬁcant change in airway neutrophils (Fig. 4I). In addition,
DEX did not inhibit SAA induction of CXCL1/2 expression (Fig.
4J). As a control for acute inﬂammation, the same dose of DEX
displayed a 49% reduction in LPS (1 μg, i.n.) triggered BALF
neutrophilia (LPS; 7.0 ± 0.7 × 105 vs. DEX-LPS 3.5 ± 0.5 × 105,
P < 0.05). To evaluate whether local SAA effects were also
mediated by LTB4, levels of LTB4 in BALF were measured. SAA
did not induce measureable local LTB4 production (EIA, Cay-
man Chemicals; detection limit = 13 pg/mL), and treatment with
15-epi-LXA4 did not signiﬁcantly change LTB4 levels.
SAA Localized with Macrophages in COPD Lungs. The presence and
cellular distribution of SAA was assessed immuno-histochemi-
cally in resected human lung tissue (Table S2). Control subjects
were negative for SAA in seven of eight lung specimens, with one
specimen displaying moderate staining. In contrast, a moderate
staining pattern within the parenchyma was observed in 7 of 22
COPD lung specimens. No reactivity was observed in 9 of 22 lung
specimens with clinically stable comorbid COPD. Intense SAA
immunoreactivity was observed in 6 of 22 COPD specimens that
were diffuse in nature and localized to the submucosa, vascular,
and bronchoalveolar compartments (Fig. 5A). CD68+ macro-
phages were present in BALF and lung parenchyma (Fig. 5B)
and colocalized with SAA-positive regions. Because SAA can
serve as a precursor for amyloid protein AA serial sections were
stained with Congo red. No sample showed observable bi-
refringence, indicating the absence of insoluble AA amyloid ﬁbril
deposition. Smoking history was not signiﬁcantly different across
the three SAA staining proﬁles [No SAA: mean 47 pack years
(10–140), moderate SAA: 59 pack years (30–120), and intense
SAA: 36 pack years (25–48)]. Additionally FEV1% predicted was
not signiﬁcantly different across the staining proﬁles [No SAA:
mean 79% (54–89), moderate SAA 77% (52–91), and intense
SAA 78% (66–85)].
A positive correlation between SAA mRNA and protein was
found in BALF (P = 0.01, r = 0.83) (Table S1), implicating al-
veolar macrophages as a major candidate for production of
BALF SAA. BALF cytospot immunostaining conﬁrmed that
alveolar macrophages from COPD subjects were positive for
SAA, with prominent staining observed in the cytoplasmic region
(Fig. 5C). The regulation of SAA expression was further in-
vestigated in human macrophages (THP-1 cell line) exposed to
bacterial LPS (1 μg/mL), which is abundant in the airways during
AECOPD (15). LPS induced THP-1 SAA mRNA levels by 25 ±
12-fold (Fig. 5D). DEX also induced SAA mRNA by 90 ± 23-
fold, and synergistically increased LPS-induced SAA expression
in a dose-dependent manner with 10−6 M DEX plus LPS, re-
sulting in a 2,564 ± 754-fold increase. The calculated half max-
imal concentration (EC50) was 43 nM (Fig. 5E). As a control,
DEX (10−6 M) effectively decreased LPS-induced IL-8 release
by 76% in the same incubations (Fig. 5F). To further investigate
whether innate stimuli relevant to COPD and infectious
AECOPD can directly promote de novo local synthesis of SAA
in airway tissue, SAA mRNA in whole lung from mice treated
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under three separate conditions were determined (Fig. S4).
BALB/c mice subchronically exposed to cigarette smoke for 4 d
displayed a 34-fold increase in SAA expression (Fig. S4A). In-
tranasal administration of LPS (10 μg per mouse) induced a 350-
fold peak increase in SAA 24 h following challenge (Fig. S4B). In
addition, intranasal administration of inﬂuenza (HKx31) tran-
siently induced SAA expression, peaking at day 5 postinfection
(17-fold) (Fig. S4C).
The acute phase SAA isoforms (SAA1 and SAA2) are 95%
homologous and indistinguishable by qPCR, whereas mouse
SAA3 (71% sequence identify with SAA1) is a pseudogene in
humans (16). The in vivo expression of SAA isoforms was
assessed in murine lung tissue following LPS challenge in the
presence of a clinically used inhaled GC, budesonide (Fig. S5).
Budesonide (intranasally) induced SAA1/2 expression ∼ﬁvefold
and LPS induced SAA1/2 by greater than 20-fold (Fig. S5B).
Airway administration of budesonide (10 μg) 6 h after LPS (3 μg)
did not inhibit peak neutrophilic airway inﬂammation (Fig. S5A)
or SAA1/2 lung transcript expression (Fig. S5B), whereas SAA3
was reduced by 50% (Fig. S5C). Secreted SAA in BALF was
increased by budesonide, in particular after concomitant LPS
F
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Fig. 3. Relationship between SAA and LXA4 during AECOPD. (A) LXA4 and
(B) SAA concentration (nM) in matching blood samples from COPD subjects
during (i) the acute phase of an exacerbation (AECOPD) and at (ii) clinical
recovery (Resolution) (n = 10, *P < 0.05 by Wilcoxon-matched paired t test).
(C) The relative ratio of SAA/LXA4 was determined for the matching AECOPD
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AECOPD phase, demonstrating a signiﬁcant correlation with LTB4 only (
δP =
0.002, r = 0.87 Pearson correlation).
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challenge for 24 h (Fig. S5D). In contrast, the neutrophil agonists
CXCL1, CXCL2, IL-17A) and G-CSF were inhibited by at least
50% by budesonide (Fig. S5 G–J). LPS-initiated increases in
ALX/FPR2 expression were also decreased by budesonide (Fig.
S5E). ANXA1 expression was not signiﬁcantly changed by either
LPS or budesonide (Fig. S5F).
Discussion
In this study, we have demonstrated that SAA is a potent and
highly efﬁcacious proinﬂammatory mediator in the lung that is
markedly up-regulated in exacerbations and produced locally, in
response to diverse innate stimuli. SAA was also intimately as-
sociated with neutrophil accumulation and activation in clinical
samples and experimental models. Whereas LXA4 and 15-epi-
LXA4 can suppress SAA actions via a noncompetitive interac-
tion of an allosteric type, the very high levels of SAA in COPD
may overwhelm this defense mechanism. Induced sputum from
subjects with COPD contain both LXA4 and 15-epi-LXA4 (6),
and we demonstrate SAA levels in excess of 50 ng/mL in COPD
BALF. Furthermore, GCs, the most effective current agents to
suppress mucosal inﬂammation, increased rather than sup-
pressed SAA production. Although SAA has been shown to
target other receptor complexes, including Scavenger receptor
class B type I (SR-BI) (17), receptor for advanced glycation end-
products (RAGE) (18), Toll-like receptor (TLR) 4 (19), and
TLR2 (20), here we provide evidence that 15-epi-LXA4 can
ameliorate the adverse effects of SAA in vivo. Because bioactive
stable analogs of 15-epi-LXA4 have been prepared and proven
efﬁcacious in murine models of lung inﬂammation (21), the
present translational ﬁndings are unique in their demonstration
of a clinical indication for LX stable analogs in COPD.
In addition to COPD, severe asthma is also characterized by
GC refractory and persistent inﬂammation. Although the airway
neutrophila of severe asthma appears to stem, in part, from in-
creased proinﬂammatory leukotriene production and a defect in
anti-inﬂammatory LX generation (22), AECOPD was associated
with increased LXA4 without signiﬁcant change in the relative
metabolic fate of arachidonic acid to LTB4 and LXA4. The
majority (7 of 10) of acute episodes were associated with an
increase in LXA4 levels during an AECOPD. This heteroge-
neous response may reﬂect alternative resolution phenotypes
previously described, where early and late resolvers were dis-
criminated on the basis of differences in temporal LX generation
(23). During AECOPD, high amounts of circulating SAA were
also signiﬁcantly greater than ANXA1, which can interact with
ALX/FPR2 receptors to block neutrophil diapadesis (14). De-
livery of SAA to the lungs in vivo proved sufﬁcient to facilitate
airway neutrophilia. This response was inhibited by concurrent
instillation of equal amounts of 15-epi-LXA4 with SAA. LXA4 is
an autacoid that is rapidly generated and rapidly inactivated at
local sites of inﬂammation, so only a small fraction of the in-
tranasal exogenous lipoxin would be available to the lower re-
spiratory tract. The natural isomer 15-epi-LXA4 displays a mod-
estly prolonged half-life (∼twofold) (reviewed in ref. 24), but it is
also rapidly inactivated in the lung. Thus, intranasal administra-
tion of SAA and 15-epi-LXA4 was performed to demonstrate
proof-of-principle that SAA-initiated acute lung inﬂammation
can be decreased by LX signaling, and proof of therapeutic utility
was demonstrated. The ﬁndings presented here demonstrate that
blocking SAA in vivo is achievable with ALX/FPR2-targeted
compounds in 10- to 100-times excess doses. Given that there are
numerous precedents in G protein-coupled receptor pharma-
cology where it has been possible to make drugs with up to 1,000-
fold higher afﬁnity than the endogenous agonist, it is very likely
that clinically useful drugs exploiting this mechanism can be
created. Taken together, these ﬁndings suggest that the relative
amounts of SAA and LXs can modulate the neutrophil-rich air-
way inﬂammation in COPD and point to a pivotal role for ALX/
FPR2 receptor signaling in airway epithelial cells for integrating
the host functional response to these mediators.
The distribution of tissue SAA was widely dispersed in most
specimens, and also concordantly localized with ALX/FPR2
receptors that were preferentially distributed along the epithelium,
including the basolateral margin; placing SAA and ALX/FPR2
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Fig. 5. SAA is elevated in COPD airways and colocalizes with BAL and tissue macrophages. (A) A representative specimen of Intense SAA staining in COPD. (B)
Serial sections were immunostained for CD68+ macrophages (50×magniﬁcation). (C) SAA expression in bronchoalveolar COPD macrophages was detected by
immunocytochemistry. (D) SAA expression was measured by qPCR in THP-1 cells treated with LPS (1 μg/mL) or DEX (10−6 M) for 24 h. (E) The combination of
DEX and LPS was next assessed and normalized to LPS alone, which was designated as 100%. Note that because of the large synergistic effect of DEX and LPS
(35,000% at 10−6 M DEX), the y axis was log-transformed. The DEX concentration dose–response curve for LPS treated THP-1 cells generated an EC50 of 43 nM.
(F) IL-8 levels were also measured at the DEX dose (10−6 M), causing maximal induction of SAA, demonstrating effective suppression of IL-8. The data are
expressed as a percentage of the LPS response and the mean ± SEM for n = 4–5, #P < 0.05.
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in close proximity. Here, ALX/FPR2 expression markedly en-
hanced SAA-mediated mucosal inﬂammatory responses by hu-
man airway epithelial cells. Of note, genetic deletion of ALX/
FPR2 in mice identiﬁed a critical role for this receptor in SAA-
mediated leukocyte chemotaxis (25). ALX/FPR2 expression was
prominent at the apical and basolateral epithelial surfaces of
COPD airways. Bronchial cell injury induces ALX/FPR2 epi-
thelial expression, in part, via prostaglandin E2 (PGE2) (13) and
the staining pattern in COPD airways is consistent with increased
PGE2 levels observed in COPD airways (26). Of interest, GCs can
up-regulate ALX/FPR2 expression in leukocytes (27), suggesting
potential ampliﬁcation of proinﬂammatory signaling in conjunc-
tion with GC-induced increases in SAA.
Although extrahepatic SAA production by tissue macrophages
has recently been recognized in other chronic inﬂammatory
conditions, notably rheumatoid arthritis (28, 29) and atheroscle-
rosis (30), the ﬁndings herein point to SAA as a major disease
locus in lung disease, with CD68+ macrophages as a potentially
important source for airway SAA (but does not exclude epithe-
lium, ﬁbroblasts or other cells as extrahepatic contributors). Be-
cause SAA expression was markedly induced by DEX, SAA
may prove to be a major candidate for GC-induced neutrophil
survival. Annexin A1 (Lipocortin 1) is another prominent GC-
inducible protein, but Annexin A1 and related degradative pep-
tides serve as ALX/FPR2 ligands that, like LXs, transduce anti-
inﬂammatory signals for neutrophils (14). The marked induction
of SAA by GCs and in AECOPD would likely also block ALX/
FPR2 signaling by Annexin A1 and related anti-inﬂammatory
peptides. Our results are unique in their characterization of de
novo SAA isoform expression in inﬂamed lungs and demonstrate
that budesonide, a clinically used GC, increased SAA1/2 lung
expression. These ﬁndings are consistent with SAA1 containing
a functional glucocortoid response element (GRE) in its pro-
moter region that is induced by GCs through a GC receptor
(GR)-dependent manner (31, 32). Taken together, these ﬁndings
may help to explain the clinical observations that inﬂammation in
COPD is refractory to inhaled GCs (33).
In summary, our results demonstrate that SAA and LXs can
regulate airway inﬂammatory responses in vitro and in vivo via
interactions with ALX/FPR2 receptors, and that proinﬂam-
matory SAA is disproportionately expressed relative to pro-
resolving LXs in AECOPD. Because SAA is associated with
AECOPD severity (11), the imbalance during severe events may
represent a fundamental mechanism for prolonging and in-
tensifying inﬂammation that is associated with AECOPD-related
hospitalization, respiratory failure, and death. Findings presented
here suggest that harnessing natural LX counter regulatory
pathways with stable LXA4 analogs holds promise as a unique
GC-independent therapeutic approach to reducing SAA-medi-
ated inﬂammation in COPD and dampening the severity of epi-
sodes of AECOPD.
Methods
Full details are provided in SI Methods. Brieﬂy, there were three separate
patient cohorts involving a total of 91 patients, as summarized in Table S3.
See Table S4 for AECOPD characteristics.
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